Although I support Capstone in the long term, I agree with this comment. Two weeks ago I sent a letter to investor relations indicating exactly the same thing. Sales and general Administration costs are way out of whack. Research and Development costs should not agitate a loss to widen/increase a loss. R&D can come out of net profits only to the extent of positive cash flow. Further, I indicated as a past Series 7 & 65 holder I have no apprehension to working the phones in the next 3 to six months to the managers of CPST holdings at institutions across America. -Gary Anderson
Gary, I plan to vote against the entire BOD in the upcoming proxy as it is time for new leadership at CPST. IMHO, the present group has done all it can and promises way too much for what they can deliver. Your thoughts??